Effect of supplementation in treatment of patients with diabetic hemodialysis

Clinical trial of the effect of vitamin D supplementation compared with the placebo on gene expression related to inflammation and oxidative stress in patients with diabetic hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201701035623N101

Enrollment

Registered

2017-01-08

Start date

2016-12-09

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: 50000 IU vitamin D (Zahravi, Tabriz, Iran), once every 2 weeks, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), once ever

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic hemodialysis Aged 18 to 80 years

Exclusion criteria

Exclusion criteria: Taking vitamin D, antioxidant and anti-inflammatory supplements such as vitamins E and C, omega-3 fatty acids Taking immunosuppressive medications within 3 months prior to the enrollment in the study

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IL-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IL-6. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IL-4. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

TNF-a. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IL-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IL-6. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IL-4. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

—

Secondary

Measure	Time frame
TGF-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;NFK-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;VEGF. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IFN-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

TGF-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;NFK-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;VEGF. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;IFN-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026